SpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round for the Spanish genetic medicines specialist.
Key Takeaways
- The Barcelona-headquartered firm has closed an impressive $135m series B round.
The Barcelona-based group has closed a $135m series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?